FY 2026 saw record revenue, cash generation, and market leadership, with strong growth in both domestic and international markets. Strategic milestones included onshore manufacturing, proprietary IP development, and a digital health initiative, positioning for accelerated growth in FY 2027.Based on…
FY 2026 saw record revenue, cash generation, and market share gains, with Biome Daily becoming Australia's top probiotic. International expansion delivered high margins and strong growth, especially in Canada and Ireland, while new manufacturing and digital initiatives set the stage for accelerated…
Record FY26 sales revenue of $23.9m, up 30% year-over-year, with Biome Daily leading Australian pharmacy probiotics. Q4 saw strong cash inflow, reduced debt, and expansion of clinical trials, while onshore manufacturing is set to boost efficiency in FY27.Original document: Biome Australia Ltd [BIO…
Biome Australia Price Target Cut 25% to A$0.75/Share by Bell Potter
Specialist live biotherapeutics health company Biome Australia ASX:BIO has reported a record sales revenue of $23.9 million for the 2026 financial year, representing a 30% jump on the previous year.Delivered in a difficult environment for the broader consumer health sector, the result was led by th…
Biome Australia Ltd ASX:BIO:
